Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GelGeneCircuit

Financiado

Cerrado

Cancer heterogeneity and therapy profiling using bioresponsive nanohydrogels for...

Cancer heterogeneity and therapy profiling using bioresponsive nanohydrogels for the delivery of multicolor logic genetic circuits. Conventional cancer therapies suffer from poor efficacy owing to the lack of efficient delivery systems and to the inherent tumor heterogeneity that requires multi-modal approach to abrogate cancer progression. Nanotechnology hold... ver más

31/01/2025

UNL

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2025-01-31

ERC-2019-STG: ERC Starting Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UNL

1.44M€ | Lider

AIRBUS DEFENCE AND SPACE

3.38M€ | Participante

iMM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NANOTHER Integration of Novel Nanoparticle based Technology for Thera... 12M€ Cerrado

MyNano Towards the design of Personalised Polymer based Combination... 2M€ Cerrado

NANONC Nanomaterials in Oncology Exploiting the Intrinsic Cancer S... 2M€ Cerrado

HybridNP Remotely actuated re-shaped nanocarriers for tumour targetin... 150K€ Cerrado

CellularNanoMachines Development of Stimuli Responsive Nanoparticle carrying T ly... 241K€ Cerrado

RTI2018-093831-B-I00 SISTEMAS MULTIVALENTES PARA NANOMEDICINA 182K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2019-10-14
Fecha Fin: 2025-01-31

Líder del proyecto

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Conventional cancer therapies suffer from poor efficacy owing to the lack of efficient delivery systems and to the inherent tumor heterogeneity that requires multi-modal approach to abrogate cancer progression. Nanotechnology holds promise to address these drawbacks, as the use of (bio)nanomaterials for diagnostics and therapy has been gaining momentum over the last years. The main goal of this project is to develop a novel and facile platform capable of profiling both the therapy outcome and heterogeneity in cancer, by using bioresponsive nanohydrogels for the delivery of logic multicolor synthetic gene circuits. These logic synthetic gene circuits will be designed as a biobarcode of multicolor RNA circuits embedded in hybrid nanoparticles and doped in hydrogels for local therapy in breast cancer in vivo. Using cell-type specific promoters, the multicolor miRNA circuits will be expressed specifically to each type of the cells of the tumor microenvironment. Subsequently, this will permit to evaluate the therapeutic efficacy in a cell-by-cell basis and to profile the tumor heterogeneity across different breast cancer types. In order to potentiate the translation of this ground-breaking platform into clinics and precision medicine, novel de-regulated miRNA targets will be identified based on screens performed in breast cancer patient-derived tumors that better reflect the heterogeneous tumor microenvironment in a patient-by-patient basis. In sum, the material platforms developed herein and newly identified biological targets can be harnessed to design effective cancer treatments that go beyond breast cancer. The project is highly versatile and multidisciplinary and this system can be easily adapted to target any cancer cell type and molecular mechanisms and translated to clinical testing.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores